Megakaryocyte growth factors and acute myeloid leukemia
TO THE EDITOR I read with interest the review paper by Hofmann and colleagues 1 on the potential role of megakaryocytic growth factors in patients with thrombocytopenia. Overall, the authors nicely summarize a very rapidly growing literature in the field, and bring several important questions to the fore. However, I believe the wrong impression is left in their discussion of the effects of thrombopoietin in patients undergoing standard dose chemotherapy for acute myelogenous leukemia. On this topic Hofmann and colleagues cite an abstract submitted to the 1996 meeting of the American Society of Hematology, 2 and suggest that thrombopoietin had a favorable effect on platelet recovery (22 days to unsupported platelet count у20 000/l in the two thrombopoietin treatment groups vs 27 days in the placebo group). Although the printed abstract clearly provides these data, when the study group had doubled in size by the time the paper was presented in December 1996, the favorable differences between the treatment and placebo groups disappeared, and the lead author, Dr Archimbaud, concluded there was no effect of thrombopoietin when given to their patients 
